DiaMedica Therapeutics Inc.DMAC announced that it initiated a pivotal phase II/III study ReMEDy2 to evaluate its recombinant kallikrein-1 (KLK1) protein candidate, DM199, as a potential treatment of acute ischemic stroke (AIS). Data from this study will…

Click here to view the original article.